GALNT2-Congenital Disorder of Glycosylation

Mendelian MONDO:0030043 Pathograph 20 Show in embeddings browser Congenital Disorder of Glycosylation

A recessive congenital disorder of glycosylation caused by loss of function of GALNT2, which encodes GalNAc-T2, one of twenty isoenzymes that initiate mucin-type O-linked glycosylation in the Golgi. Patients have global developmental delay, intellectual disability with a disproportionate language deficit, autistic features, epilepsy, chronic insomnia, white matter change on MRI, dysmorphic features, short stature, and strikingly low HDL cholesterol. Two features make this disease unusual among the CDGs and shaped this entry. The first is that the twenty GalNAc-T isoenzymes overlap heavily in substrate range, so losing one of them should in principle be buffered. What makes GALNT2-CDG a disease is the small set of substrates for which GalNAc-T2 is *not* redundant. Apolipoprotein C-III is the best characterised of those, and its complete loss of O-glycosylation in every reported patient is what turns an enzyme deficiency into a measurable biochemical phenotype. The entry is built around that non-redundancy rather than around a general loss of O-glycosylation, because the general loss does not occur. The second is that apoC-III is a biomarker of the enzyme defect, not the cause of the neurological disease. The low HDL is downstream of apoC-III hypoglycosylation; the developmental phenotype is not. Which brain substrate carries the neurological phenotype is unknown, and the entry records that as a knowledge gap rather than implying that the lipid arm explains the disease. Keeping those two arms separate is the main curation decision here. A third point is worth stating because it affects how the evidence should be read. The GALNT2 locus is one of the best-replicated common-variant HDL loci in human genetics, so there is a large literature associating GALNT2 with lipid traits in the general population. That literature is about common regulatory variation with small effects, not about this disease. It is cited here only where it establishes the same enzyme-substrate relationship, and is labelled as population-genetic evidence.

Ask OpenScientist

Ask a research question about GALNT2-Congenital Disorder of Glycosylation. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
10
Phenotypes
2
Gaps
20
Pathograph
1
Genes
3
Medical Actions
2
Differentials
2
Models
1
Deep Research
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Seven patients across four families with biallelic loss of function, which is the standard pattern for a congenital disorder of glycosylation.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"Here, we report the clinical, biochemical, and molecular features of seven patients from four families with GALNT2-congenital disorder of glycosylation (GALNT2-CDG), an O-linked glycosylation disorder."
The multiplex-family structure on which the recessive inference rests.
?

Discussions and Knowledge Gaps

2
Which GalNAc-T2 substrate or substrates mediate the neurodevelopmental phenotype of GALNT2-CDG?
KNOWLEDGE GAP galnt2_brain_substrate_unknown
Attached to
pathophysiology#Neurodevelopmental Dysfunction pathophysiology#Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
The lipid arm of this disease is mechanistically complete: a named substrate, a measured loss of its glycosylation, and a downstream clinical readout. The neurological arm, which is what actually disables patients, has none of that. The defining paper attributes it to non-redundant substrates in various tissues including brain, without identifying any of them, and the causal edge in this entry is typed INDIRECT_UNKNOWN_INTERMEDIATES to reflect that. The gap is tractable rather than merely acknowledged: the Galnt2-null glycoproteomic atlas already lists proteins that lose GalNAc-T2-specific glycans, so the candidates exist and the missing step is testing which of them matters in brain. It also has a practical consequence. Any therapeutic strategy aimed at the neurological phenotype needs a target, and there is currently no candidate to aim at.
Proposed experiments
Brain-restricted O-glycosite mapping and functional follow-up in Galnt2-null rodents
galnt2_brain_glycosite_mapping
Apply the same quantitative O-GalNAc glycoproteomics to brain regions in Galnt2-null animals, restrict to sites lost in brain but retained elsewhere, and test the resulting candidates for a neurodevelopmental role.
Readouts
Brain-specific GalNAc-T2-dependent O-glycosites
pathophysiology#Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
Direction: DECREASED
Interpretation: A brain substrate lost only in the null identifies a candidate mediator.
Would support
pathophysiology#Neurodevelopmental Dysfunction
Would refute
pathophysiology#Neurodevelopmental Dysfunction
Supporting outcome
  • One or more neuronal or glial proteins with essential developmental functions lose O-glycosylation specifically in brain, and their independent disruption reproduces part of the behavioural phenotype.
Refuting outcome
  • No brain protein loses O-glycosylation beyond those already lost in other tissues, which would move the explanation away from a brain-specific substrate towards a systemic or developmental mechanism.
Why does loss of one of twenty GalNAc-T isoenzymes produce a severe multisystem disease when the family is largely redundant?
KNOWLEDGE GAP galnt2_redundancy_paradox
Attached to
pathophysiology#Loss of GalNAc-T2 Initiation of Mucin-Type O-Glycosylation
This is the question the disease poses to glycobiology rather than a gap in the clinical description. Redundancy is the family's defining property, and yet losing one member is not tolerated. The answer implied by the literature is that non-redundancy is site-specific rather than protein-specific - a given isoenzyme is the only one that will modify a particular residue in a particular sequence context - but which features of a site make it GalNAc-T2-exclusive is not established. Worth stating because it governs how much can be generalized from apoC-III. ApoC-III is the one non-redundant substrate that happens to be abundant, secreted and easy to assay, and there is no reason to think it is representative of the others.
⚙

Pathophysiology

7
Biallelic GALNT2 Loss-of-Function
The initiating lesion: loss of function of both GALNT2 alleles, removing the GalNAc-T2 isoenzyme.
Genetic context variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION
Downstream
Loss of GalNAc-T2 Initiation of Mucin-Type O-Glycosylation Removing the enzyme removes the transfer step it catalyses.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"GALNT2 encodes the Golgi-localized polypeptide N-acetyl-d-galactosamine-transferase 2 isoenzyme."
Identifies the gene product and its compartment, which is what the next node is about.
Loss of GalNAc-T2 Initiation of Mucin-Type O-Glycosylation
GalNAc-T2 catalyses the first committed step of mucin-type O-glycosylation, adding GalNAc to serine or threonine on a secreted or membrane protein as it passes through the Golgi. This is where the redundancy question sits. GalNAc-T2 is one of a family, its expression is broad rather than tissue-restricted, and for most substrates another isoenzyme can do the same job. So the consequence of losing it is not a global O-glycosylation failure but a failure confined to the sites only GalNAc-T2 will modify.
initiation of mucin-type O-glycosylation GO:0016266 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased initiation of mucin-type O-glycosylation, annotated with protein O-linked glycosylation via N-acetylgalactosamine (GO:0016266). GO:0016266 is a biological process from the Gene Ontology. ↓ DECREASED
GalNAc-T2 transferase activity GO:0004653 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves absent GalNAc-T2 transferase activity, annotated with polypeptide N-acetylgalactosaminyltransferase activity (GO:0004653). GO:0004653 is a molecular function from the Gene Ontology. ∅ ABSENT
Golgi apparatus GO:0005794 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves Golgi apparatus (GO:0005794). GO:0005794 is a cellular component from the Gene Ontology.
Downstream
Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites Sites no other isoenzyme modifies are left unglycosylated.
Show evidence (2 references)
PMID:32293671 SUPPORT Human Clinical
"GALNT2 is widely expressed in most cell types and directs initiation of mucin-type protein O-glycosylation."
States the enzyme's step and its broad expression - the latter being why the phenotype is multisystem rather than organ-restricted.
PMID:37862385 SUPPORT Model Organism
"The family of GalNAc-Ts (GalNAcpolypeptide:N-Acetylgalactosaminyl transferases) catalyzes the first committed step in the synthesis of O-glycans, which is an abundant and biologically important protein modification."
Establishes that the lost step is the committed first step of the pathway, which is why no downstream enzyme can compensate for a site that is never initiated.
Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
The pivot of the disease. Most O-glycosites survive the loss of one isoenzyme; a minority do not, and those are what produce the phenotype. Apolipoprotein C-III is the substrate this was established on, and it is described as non-redundant for GalNAc-T2 explicitly: all seven patients lost its O-glycosylation entirely. That makes apoC-III both the mechanistic anchor and the diagnostic test. Beyond apoC-III the substrate set has been mapped rather than enumerated one at a time: glycoproteomics of Galnt2-null mouse tissue identifies a network of proteins lacking GalNAc-T2-specific glycans. That work is murine and is graded accordingly.
Animal models
Galnt2-null mouse Mouse measures Used as the system in which the GalNAc-T2-dependent O-glycosite network was mapped by quantitative glycoproteomics. Listed as MEASURES rather than RECAPITULATES because its role here is as an assay substrate: it is where the substrate set was determined, not a model of a lesion.
Downstream
ApoC-III Hypoglycosylation and Altered Lipoprotein Metabolism The lipid arm, which runs through a named and measured substrate.
Insulin Receptor Hypoglycosylation and Altered Energy Homeostasis A second named substrate, and the one that plausibly connects the enzyme defect to the growth phenotype.
Neurodevelopmental Dysfunction The neurological arm. Deliberately typed as having unknown intermediates: no brain substrate of GalNAc-T2 has been shown to mediate the developmental phenotype, and the entry does not name one.
Dysmorphic Features The dysmorphism has no identified substrate either. It is drawn from this node rather than from the neurodevelopmental node because it is a morphogenetic rather than a neurological consequence; the source attributes both to non-redundant substrates it does not name.
Show evidence (2 references)
PMID:32293671 SUPPORT Human Clinical
"All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant substrate for GALNT2."
Establishes both the non-redundancy and its complete penetrance across the reported cohort. This single sentence carries the mechanism and the biomarker together.
PMID:37862385 SUPPORT Model Organism
"We examined the Galnt2-null mouse model, which phenocopies congenital disorder of glycosylation involving GALNT2 and revealed a network of glycoproteins that lack GalNAc-T2-specific O-glycans."
Extends the substrate claim from one protein to a mapped network, in mouse tissue.
ApoC-III Hypoglycosylation and Altered Lipoprotein Metabolism
ApoC-III normally carries a mucin-type core-1 O-glycan and circulates in glycoforms that differ in sialylation. Loss of GalNAc-T2 abolishes the initiating GalNAc, so no glycoform is made at all. Because apoC-III regulates triglyceride-rich lipoprotein handling, this shifts plasma lipids, and the clinical readout is a low HDL cholesterol. The direction is corroborated from a second, entirely independent direction: common variation at the GALNT2 locus in population cohorts shifts apoC-III glycoform proportions and shifts HDL and triglycerides with them.
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
Downstream
Decreased HDL Cholesterol The measurable lipid endpoint.
Show evidence (2 references)
PMID:32293671 SUPPORT Human Clinical
"Patients with GALNT2-CDG generally exhibit a syndrome characterized by global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features, decreased stature,..."
The clinical HDL finding, quoted from the sentence that lists the whole syndrome.
PMID:37834292 SUPPORT INDIRECT Human Clinical
"On a genome-wide scale, we confirmed that the GALNT2-gene plays a major role i O-glycosylation of apolipoprotein-CIII, with subsequent associations with lipid parameters."
Independent population-genetic corroboration that GALNT2 controls apoC-III O-glycosylation and that this tracks with lipid traits. Graded INDIRECT because it concerns common regulatory variation in the general population, not biallelic loss of function, so the claim about this disease follows by an inference step rather than being asserted.
Insulin Receptor Hypoglycosylation and Altered Energy Homeostasis
The second identified non-redundant substrate, and the reason the entry does not treat apoC-III as the whole of the mechanism. The insulin receptor is a GalNAc-T2 substrate, and Galnt2-null mice show altered insulin signalling, reduced adiposity and a shift in which fuel they burn. This matters for interpreting the human phenotype. Short stature and poor growth are core features of GALNT2-CDG and have no explanation in the lipid arm. A defect in insulin receptor glycosylation is a candidate explanation with a named substrate behind it, which is more than the neurological arm has. The caution is that the demonstration is murine. No study has shown altered insulin receptor glycosylation or insulin signalling in a GALNT2-CDG patient, so the human claim is an extrapolation and the entry marks it as such rather than curating a growth mechanism it cannot source in humans.
Downstream
Short Stature The edge this node's description already argues for in prose and did not draw. Typed with unknown intermediates rather than DIRECT for the reason stated above: the substrate identification and the growth phenotype are both murine, and no study has measured insulin receptor glycosylation or insulin signalling in a patient. It is the only candidate explanation for the growth phenotype with a named substrate behind it, which is why the edge is drawn at all rather than left out.
Show evidence (2 references)
PMID:35304331 SUPPORT INDIRECT Model Organism
"we identify the insulin receptor as a novel substrate of GalNAc-T2 and demonstrate that Galnt2-/- mice exhibit decreased adiposity, alterations in insulin signaling and a shift in energy substrate utilization in the inactive phase."
Identifies the substrate and the metabolic consequence of losing its glycosylation. INDIRECT with respect to the human disease: the substrate identification and the signalling phenotype are both murine, so applying them to patients requires an inference step.
PMID:35304331 SUPPORT INDIRECT Model Organism
"It has recently become clear that loss of GALNT2 in rodents, cattle, nonhuman primates, and humans should be regarded as a novel congenital disorder of glycosylation that affects development and body weight."
States that the growth/body-weight consequence of GALNT2 loss holds across four species including humans, which is what makes the murine insulin-receptor mechanism worth recording against the human growth phenotype rather than discarding.
Neurodevelopmental Dysfunction
The clinically dominant arm of the disease and the least mechanistically explained. What is established is that it is not secondary to the lipid phenotype and that it is reproduced in rodents, so it is a consequence of losing the enzyme rather than an ascertainment artefact of the human series. What is not established is the intermediate. No brain substrate of GalNAc-T2 has been linked to the phenotype, and the defining paper attributes it to multiple non-redundant substrates in various tissues without naming the relevant ones.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology. oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
Animal models
Galnt2-null mouse Mouse partially recapitulates Reproduces poor growth and neurodevelopmental abnormality, with cerebellar motor deficits, decreased sociability, and impaired sensory integration on behavioural testing.
Galnt2-deficient rat Rat partially recapitulates Reproduces poor growth and neurodevelopmental abnormalities.
Downstream
Global Developmental Delay The cardinal neurodevelopmental manifestation.
Intellectual Disability with Language Deficit The disproportionate language involvement is the feature that most distinguishes this disorder's cognitive profile.
Delayed Speech and Language Development The developmental counterpart of the language deficit above.
Autistic Features Reported across the cohort as part of the behavioural phenotype.
Epilepsy Nothing connects the enzyme defect to seizure susceptibility mechanistically; the association is clinical.
Chronic Insomnia Recorded as a distinct feature by the defining cohort rather than folded into the behavioural phenotype.
White Matter Changes on Brain MRI The one neurological finding with a structural correlate, and the reason oligodendrocytes are bound on this node alongside neurons. Whether the white matter change causes the clinical phenotype or accompanies it is not established, so this is drawn as a parallel consequence rather than as an intermediate.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"The multisystem nature of phenotypes in patients and rodent models of GALNT2-CDG suggest that there are multiple non-redundant protein substrates of GALNT2 in various tissues, including brain, which are critical to normal growth and development."
The authors' own framing, and the reason this node's upstream edge is typed with unknown intermediates: the substrates are inferred to exist, not identified.
Decreased HDL Cholesterol
The biochemical endpoint of the lipid arm, and in practice the finding that flags the diagnosis in a child investigated for developmental delay.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels."
States the HDL finding.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for GALNT2-Congenital Disorder of Glycosylation Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Head and Neck 1
Dysmorphic Features VERY_FREQUENT Abnormal facial shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysmorphic facial features, annotated with Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"white matter changes on brain MRI, dysmorphic features, decreased stature"
Names the dysmorphism.
Metabolism 1
Decreased HDL Cholesterol VERY_FREQUENT Decreased HDL cholesterol concentration HP:0003233 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased HDL cholesterol concentration (HP:0003233). HP:0003233 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels."
States the HDL finding.
Nervous System 7
Global Developmental Delay VERY_FREQUENT HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"Patients with GALNT2-CDG generally exhibit a syndrome characterized by global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features, decreased stature,..."
Lists the feature. Graded VERY_FREQUENT rather than OBLIGATE because the source says "generally exhibit" rather than giving a per-patient count.
Intellectual Disability with Language Deficit VERY_FREQUENT HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia"
Names intellectual disability and its language component.
Delayed Speech and Language Development VERY_FREQUENT HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"intellectual disability with language deficit"
The language deficit itself.
Autistic Features VERY_FREQUENT Autistic behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy"
Names the autistic features.
Epilepsy VERY_FREQUENT Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI"
Names epilepsy as part of the syndrome.
Chronic Insomnia VERY_FREQUENT HP:0100785 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insomnia (HP:0100785), qualified as temporality chronic. HP:0100785 is a phenotype from the Human Phenotype Ontology.
Temporal: CHRONIC
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI"
Names the insomnia and its chronicity.
White Matter Changes on Brain MRI VERY_FREQUENT Abnormal cerebral white matter morphology HP:0002500 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is White matter changes on brain MRI, annotated with Abnormal cerebral white matter morphology (HP:0002500). HP:0002500 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features"
Names the MRI finding, without a pattern, which is why the binding is the general term.
Growth 1
Short Stature VERY_FREQUENT HP:0004322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"white matter changes on brain MRI, dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels."
Names decreased stature. The mechanism is unexplained in humans; the insulin receptor node above records the murine candidate explanation and its limits.
🧬

Genetic Associations

1
GALNT2
Gene: GALNT2 hgnc:4124 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GALNT2 (hgnc:4124). hgnc:4124 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"GALNT2 encodes the Golgi-localized polypeptide N-acetyl-d-galactosamine-transferase 2 isoenzyme."
Establishes the gene product and its subcellular location.
💊

Medical Actions

3
Antiseizure Pharmacotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Small molecule
Symptomatic management of the epilepsy. No GALNT2-CDG-specific antiseizure data exist and no agent is recommended here on disease-specific grounds; the entry records the treatment target without asserting a drug choice.
Mechanism Target:
MODULATES Epilepsy — Suppresses the seizure phenotype without acting on the glycosylation defect that produces it.
Developmental and Educational Support
Action: developmental and educational interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is developmental and educational intervention, annotated with Rehabilitation (NCIT:C15315). NCIT:C15315 is a clinical intervention from the NCI Thesaurus. Ontology label: Rehabilitation NCIT:C15315
Platform: Behavioral / lifestyle
Speech and language therapy has the clearest rationale given that language is disproportionately affected. As with the antiseizure entry, this is general practice for a neurodevelopmental disorder rather than a GALNT2-CDG finding.
Mechanism Target:
MODULATES Neurodevelopmental Dysfunction — Addresses the functional consequences of the neurodevelopmental phenotype. It does not act on the mechanism, which is unidentified.
Genetic Counselling
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Platform: Behavioral / lifestyle
Autosomal recessive, 25% recurrence risk per pregnancy for carrier couples.
🔬

Diagnosis

3
Apolipoprotein C-III Glycoform Analysis
The disease-specific biochemical test. Because apoC-III is a non-redundant GalNAc-T2 substrate, its complete loss of O-glycosylation is a direct readout of the enzyme defect - unlike transferrin isoform analysis, which is the standard CDG screen and interrogates N-glycosylation, a pathway this disease does not affect. That distinction is the practical point: a GALNT2-CDG patient can screen normal on the routine CDG test.
Specificity, not just sensitivity. The cohort finding above establishes that every reported patient had the abnormality; it does not establish that the abnormality is specific to this disease, and the cited review names at least one acquired cause of a core 1 O-glycan biosynthesis abnormality. Treat a positive glycoform result as an indication to sequence rather than as a diagnosis. The claim that transferrin analysis is normal in this disease is an inference from the fact that GALNT2 acts on O-glycosylation while transferrin screening interrogates N-glycosylation. No cited source states it for GALNT2-CDG patients, so it is recorded here in notes rather than as an evidenced diagnostic claim.
Show evidence (3 references)
PMID:32293671 SUPPORT Human Clinical
"All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant substrate for GALNT2."
Establishes the test's sensitivity in the reported cohort: all seven patients.
PMID:34540767 SUPPORT INDIRECT Other
"IEF of serum apolipoprotein C-III (apoC-III) is recommended to perform (Figure 1) to distinguish between an exclusive N-glycosylation defect and a combined disorder of N- and O-glycosylation"
Places the apoC-III test in the standard CDG diagnostic algorithm rather than treating it as a GALNT2-CDG-specific assay. INDIRECT: this is class-level guidance for the congenital disorders of glycosylation, not a statement about GALNT2-CDG.
PMID:34540767 SUPPORT INDIRECT Other
"However, some patients could also have an abnormal biosynthesis of core 1 O-glycans, including those with hemolytic uremic syndrome due to Streptococcus pneumoniae."
The specificity caveat: an abnormal apoC-III profile is not on its own diagnostic of a GalNAc-T2 defect, which is the reason the molecular confirmation entry below exists rather than the glycoform test standing alone.
Molecular Confirmation by Next-Generation Sequencing
How the diagnosis is actually established. The apoC-III glycoform test above points at the enzyme, but every reported patient was confirmed by sequencing, and for a disorder this rare with a non-specific neurodevelopmental presentation the sequencing usually comes first: GALNT2-CDG is the kind of entity found by exome or genome sequencing in a child investigated for developmental delay, with the glycoform test used to confirm that the variants are doing what they appear to.
Show evidence (1 reference)
PMID:34540767 SUPPORT INDIRECT Other
"Since next-generation sequencing became more widely available, an improvement in diagnostics has been observed, with more patients and novel CDG subtypes being reported."
Establishes sequencing as the route by which new CDG subtypes are identified and diagnosed. INDIRECT: this is a review of the congenital disorders of glycosylation as a class, not a statement about GALNT2-CDG, which it predates in wide recognition.
Brain MRI
Not diagnostic on its own, and included because the entry curates white matter changes as a phenotype: the finding has to be looked for to be recorded. In practice the MRI is performed as part of the workup for developmental delay rather than for suspected GALNT2-CDG.
Show evidence (1 reference)
PMID:32293671 SUPPORT INDIRECT Human Clinical
"white matter changes on brain MRI"
Names the imaging finding in the defining cohort's phenotype description. INDIRECT because the source reports the finding rather than recommending the investigation.
📊

Prevalence

1
Worldwide
Cases In Literature Not yet documented
Seven patients from four families in the report that defined the disease. No prevalence estimate exists and none would be meaningful at this evidence base.
Show evidence (1 reference)
PMID:32293671 SUPPORT Human Clinical
"Here, we report the clinical, biochemical, and molecular features of seven patients from four families with GALNT2-congenital disorder of glycosylation (GALNT2-CDG), an O-linked glycosylation disorder."
The full published patient count at the time this entry was curated.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from GALNT2-Congenital Disorder of Glycosylation:

Other congenital disorders of glycosylation
Overlapping Features The clinical overlap is broad - developmental delay, epilepsy and dysmorphism are common to much of the CDG group - but the biochemical separation is clean. Most CDGs are N-glycosylation or combined disorders detectable by transferrin isoform analysis; this one is O-glycosylation only, so it separates on which assay is abnormal rather than on phenotype.
Non-syndromic causes of low HDL cholesterol
Overlapping Features Relevant in the other direction. Low HDL is common and usually has nothing to do with glycosylation; it becomes a pointer to this disease only in the presence of the neurodevelopmental phenotype. Common GALNT2 regulatory variants also lower HDL in the general population without causing disease, which is the specific confusion to avoid.
Show evidence (1 reference)
PMID:37834292 SUPPORT INDIRECT Human Clinical
"Rs4846913-A, in the GALNT2-gene, was associated with decreased apo-CIII0a. This variant was associated with increased high-density lipoprotein cholesterol and decreased triglycerides"
Documents that common GALNT2 variation shifts HDL in the general population. INDIRECT because it supports the differential-diagnostic caution by analogy rather than reporting on GALNT2-CDG patients.
🐁

Animal Models

2
Galnt2-null mouse
The principal model. It matters here for a specific reason: it establishes that the neurodevelopmental phenotype follows from loss of the enzyme rather than from ascertainment or from the consanguinity of the human families, which seven patients could not settle on their own.
Species
Mouse
Genotype
Galnt2 knockout
Publication
PMID:32293671
Pathograph links
Neurodevelopmental Dysfunction partially recapitulates fidelity: moderate observes: organism Reproduces poor growth and neurodevelopmental abnormality, with cerebellar motor deficits, decreased sociability, and impaired sensory integration on behavioural testing.
Limitations: PARTIALLY rather than fully: the human phenotype's most prominent features are epilepsy, chronic insomnia and a disproportionate language deficit, and none of those has a behavioural counterpart reported in the mouse. Decreased sociability is an analogue of the autistic features at best.
Divergences from the human mechanism
species mismatch qualifying
Language is the human phenotype's most distinctive feature and has no murine counterpart at all, so the model structurally cannot address the part of the disease that most affects patients. Epilepsy and chronic insomnia are likewise unreported in the model. SPECIES_MISMATCH is the closest available value; what is meant is an incomplete phenotype, for which ModelDivergenceTypeEnum currently has no term (see the discussion in CLAUDE.md, which anticipates INCOMPLETE_PHENOTYPE as a likely addition when the taxonomy is extended to animal models).
Readouts
Behavioural testing for sociability, motor coordination and sensory processing
Direction: ALTERED
Interpretation: Establishes a neurodevelopmental phenotype of enzyme loss in a second species.
Show evidence (1 reference)
PMID:32293671 SUPPORT Model Organism
"In behavioural studies, GALNT2-CDG mice demonstrated cerebellar motor deficits, decreased sociability, and impaired sensory integration and processing."
The behavioural findings themselves.
Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites measures fidelity: high observes: molecular Used as the system in which the GalNAc-T2-dependent O-glycosite network was mapped by quantitative glycoproteomics. Listed as MEASURES rather than RECAPITULATES because its role here is as an assay substrate: it is where the substrate set was determined, not a model of a lesion.
Limitations: The substrate network is murine. Conservation of individual O-glycosites between mouse and human is not established site by site, so the human substrate set is inferred from it rather than demonstrated.
Readouts
Quantitative O-GalNAc glycoproteomics of Galnt2-null tissue
Direction: DECREASED
Interpretation: Identifies the glycoproteins that lose GalNAc-T2-specific glycans.
Show evidence (1 reference)
PMID:37862385 SUPPORT Model Organism
"We examined the Galnt2-null mouse model, which phenocopies congenital disorder of glycosylation involving GALNT2 and revealed a network of glycoproteins that lack GalNAc-T2-specific O-glycans."
The mapping result.
Show evidence (1 reference)
PMID:32293671 SUPPORT Model Organism
"Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human phenotype, including poor growth and neurodevelopmental abnormalities."
Establishes the model as informative for the human disease, with the authors' own hedge ("much of") preserved.
Galnt2-deficient rat
A second rodent species with the same result. Recorded because cross-species reproduction is what makes the growth and neurodevelopmental phenotype a robust consequence of enzyme loss rather than a strain artefact.
Species
Rat
Genotype
Galnt2 loss of function
Publication
PMID:32293671
Pathograph links
Neurodevelopmental Dysfunction partially recapitulates fidelity: moderate observes: organism Reproduces poor growth and neurodevelopmental abnormalities.
Limitations: The abstract reports rat and mouse together without separating which findings come from which species, so nothing specific to the rat can be curated beyond the shared claim.
Show evidence (1 reference)
PMID:32293671 SUPPORT Model Organism
"Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human phenotype, including poor growth and neurodevelopmental abnormalities."
The only statement in which the rat appears; quoted rather than split, because splitting it would attribute to the rat a specificity the source does not give.
{ }

Source YAML

click to show 
name: GALNT2-Congenital Disorder of Glycosylation
creation_date: "2026-09-11T21:00:00Z"
category: Mendelian
disease_term:
  preferred_term: congenital disorder of glycosylation, type IIt
  term:
    id: MONDO:0030043
    label: congenital disorder of glycosylation, type IIt
synonyms:
- GALNT2-CDG
- CDG2T
- congenital disorder of glycosylation type IIt
- GalNAc-T2 deficiency
description: >-
  A recessive congenital disorder of glycosylation caused by loss of function of GALNT2,
  which encodes GalNAc-T2, one of twenty isoenzymes that initiate mucin-type O-linked
  glycosylation in the Golgi. Patients have global developmental delay, intellectual
  disability with a disproportionate language deficit, autistic features, epilepsy,
  chronic insomnia, white matter change on MRI, dysmorphic features, short stature, and
  strikingly low HDL cholesterol.

  Two features make this disease unusual among the CDGs and shaped this entry.

  The first is that the twenty GalNAc-T isoenzymes overlap heavily in substrate range, so
  losing one of them should in principle be buffered. What makes GALNT2-CDG a disease is
  the small set of substrates for which GalNAc-T2 is *not* redundant. Apolipoprotein C-III
  is the best characterised of those, and its complete loss of O-glycosylation in every
  reported patient is what turns an enzyme deficiency into a measurable biochemical
  phenotype. The entry is built around that non-redundancy rather than around a general
  loss of O-glycosylation, because the general loss does not occur.

  The second is that apoC-III is a biomarker of the enzyme defect, not the cause of the
  neurological disease. The low HDL is downstream of apoC-III hypoglycosylation; the
  developmental phenotype is not. Which brain substrate carries the neurological
  phenotype is unknown, and the entry records that as a knowledge gap rather than
  implying that the lipid arm explains the disease. Keeping those two arms separate is
  the main curation decision here.

  A third point is worth stating because it affects how the evidence should be read. The
  GALNT2 locus is one of the best-replicated common-variant HDL loci in human genetics,
  so there is a large literature associating GALNT2 with lipid traits in the general
  population. That literature is about common regulatory variation with small effects,
  not about this disease. It is cited here only where it establishes the same
  enzyme-substrate relationship, and is labelled as population-genetic evidence.

parents:
- Congenital Disorder of Glycosylation

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    Seven patients from four families in the report that defined the disease. No
    prevalence estimate exists and none would be meaningful at this evidence base.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report the clinical, biochemical, and molecular features of seven patients
      from four families with GALNT2-congenital disorder of glycosylation (GALNT2-CDG), an
      O-linked glycosylation disorder.
    explanation: >-
      The full published patient count at the time this entry was curated.

pathophysiology:

- name: Biallelic GALNT2 Loss-of-Function
  role: trigger
  biological_scale: MOLECULAR
  description: >-
    The initiating lesion: loss of function of both GALNT2 alleles, removing the
    GalNAc-T2 isoenzyme.
  genetic_context:
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GALNT2 encodes the Golgi-localized polypeptide N-acetyl-d-galactosamine-transferase
      2 isoenzyme.
    explanation: >-
      Identifies the gene product and its compartment, which is what the next node is
      about.
  downstream:
  - target: Loss of GalNAc-T2 Initiation of Mucin-Type O-Glycosylation
    causal_link_type: DIRECT
    description: >-
      Removing the enzyme removes the transfer step it catalyses.

- name: Loss of GalNAc-T2 Initiation of Mucin-Type O-Glycosylation
  role: mechanism
  biological_scale: MOLECULAR
  description: >-
    GalNAc-T2 catalyses the first committed step of mucin-type O-glycosylation, adding
    GalNAc to serine or threonine on a secreted or membrane protein as it passes through
    the Golgi.

    This is where the redundancy question sits. GalNAc-T2 is one of a family, its
    expression is broad rather than tissue-restricted, and for most substrates another
    isoenzyme can do the same job. So the consequence of losing it is not a global
    O-glycosylation failure but a failure confined to the sites only GalNAc-T2 will
    modify.
  molecular_functions:
  - preferred_term: GalNAc-T2 transferase activity
    term:
      id: GO:0004653
      label: polypeptide N-acetylgalactosaminyltransferase activity
    modifier: ABSENT
  biological_processes:
  - preferred_term: initiation of mucin-type O-glycosylation
    term:
      id: GO:0016266
      label: protein O-linked glycosylation via N-acetylgalactosamine
    modifier: DECREASED
  cellular_components:
  - preferred_term: Golgi apparatus
    term:
      id: GO:0005794
      label: Golgi apparatus
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GALNT2 is widely expressed in most cell types and directs initiation of mucin-type
      protein O-glycosylation.
    explanation: >-
      States the enzyme's step and its broad expression - the latter being why the
      phenotype is multisystem rather than organ-restricted.
  - reference: PMID:37862385
    reference_title: "Quantitative mapping of the in vivo O-GalNAc glycoproteome in mouse tissues identifies GalNAc-T2 O-glycosites in metabolic disorder."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The family of GalNAc-Ts (GalNAcpolypeptide:N-Acetylgalactosaminyl transferases)
      catalyzes the first committed step in the synthesis of O-glycans, which is an
      abundant and biologically important protein modification.
    explanation: >-
      Establishes that the lost step is the committed first step of the pathway, which is
      why no downstream enzyme can compensate for a site that is never initiated.
  downstream:
  - target: Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
    causal_link_type: DIRECT
    description: >-
      Sites no other isoenzyme modifies are left unglycosylated.

- name: Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
  role: mechanism
  biological_scale: MOLECULAR
  description: >-
    The pivot of the disease. Most O-glycosites survive the loss of one isoenzyme; a
    minority do not, and those are what produce the phenotype.

    Apolipoprotein C-III is the substrate this was established on, and it is described as
    non-redundant for GalNAc-T2 explicitly: all seven patients lost its O-glycosylation
    entirely. That makes apoC-III both the mechanistic anchor and the diagnostic test.

    Beyond apoC-III the substrate set has been mapped rather than enumerated one at a
    time: glycoproteomics of Galnt2-null mouse tissue identifies a network of proteins
    lacking GalNAc-T2-specific glycans. That work is murine and is graded accordingly.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant
      substrate for GALNT2.
    explanation: >-
      Establishes both the non-redundancy and its complete penetrance across the reported
      cohort. This single sentence carries the mechanism and the biomarker together.
  - reference: PMID:37862385
    reference_title: "Quantitative mapping of the in vivo O-GalNAc glycoproteome in mouse tissues identifies GalNAc-T2 O-glycosites in metabolic disorder."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We examined the Galnt2-null mouse model, which phenocopies congenital disorder of
      glycosylation involving GALNT2 and revealed a network of glycoproteins that lack
      GalNAc-T2-specific O-glycans.
    explanation: >-
      Extends the substrate claim from one protein to a mapped network, in mouse tissue.
  downstream:
  - target: ApoC-III Hypoglycosylation and Altered Lipoprotein Metabolism
    causal_link_type: DIRECT
    description: >-
      The lipid arm, which runs through a named and measured substrate.
  - target: Insulin Receptor Hypoglycosylation and Altered Energy Homeostasis
    causal_link_type: DIRECT
    description: >-
      A second named substrate, and the one that plausibly connects the enzyme defect to
      the growth phenotype.
  - target: Neurodevelopmental Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The neurological arm. Deliberately typed as having unknown intermediates: no brain
      substrate of GalNAc-T2 has been shown to mediate the developmental phenotype, and
      the entry does not name one.
  - target: Dysmorphic Features
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The dysmorphism has no identified substrate either. It is drawn from this node rather
      than from the neurodevelopmental node because it is a morphogenetic rather than a
      neurological consequence; the source attributes both to non-redundant substrates it
      does not name.

- name: ApoC-III Hypoglycosylation and Altered Lipoprotein Metabolism
  role: mechanism
  biological_scale: ORGANISM
  description: >-
    ApoC-III normally carries a mucin-type core-1 O-glycan and circulates in glycoforms
    that differ in sialylation. Loss of GalNAc-T2 abolishes the initiating GalNAc, so no
    glycoform is made at all.

    Because apoC-III regulates triglyceride-rich lipoprotein handling, this shifts plasma
    lipids, and the clinical readout is a low HDL cholesterol. The direction is
    corroborated from a second, entirely independent direction: common variation at the
    GALNT2 locus in population cohorts shifts apoC-III glycoform proportions and shifts
    HDL and triglycerides with them.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with GALNT2-CDG generally exhibit a syndrome characterized by global
      developmental delay, intellectual disability with language deficit, autistic
      features, behavioural abnormalities, epilepsy, chronic insomnia, white matter
      changes on brain MRI, dysmorphic features, decreased stature, and decreased high
      density lipoprotein cholesterol levels.
    explanation: >-
      The clinical HDL finding, quoted from the sentence that lists the whole syndrome.
  - reference: PMID:37834292
    reference_title: "Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On a genome-wide scale, we confirmed that the GALNT2-gene plays a major role i
      O-glycosylation of apolipoprotein-CIII, with subsequent associations with lipid
      parameters.
    explanation: >-
      Independent population-genetic corroboration that GALNT2 controls apoC-III
      O-glycosylation and that this tracks with lipid traits. Graded INDIRECT because it
      concerns common regulatory variation in the general population, not biallelic loss
      of function, so the claim about this disease follows by an inference step rather
      than being asserted.
  downstream:
  - target: Decreased HDL Cholesterol
    causal_link_type: DIRECT
    description: >-
      The measurable lipid endpoint.

- name: Insulin Receptor Hypoglycosylation and Altered Energy Homeostasis
  role: mechanism
  biological_scale: ORGANISM
  description: >-
    The second identified non-redundant substrate, and the reason the entry does not treat
    apoC-III as the whole of the mechanism. The insulin receptor is a GalNAc-T2 substrate,
    and Galnt2-null mice show altered insulin signalling, reduced adiposity and a shift in
    which fuel they burn.

    This matters for interpreting the human phenotype. Short stature and poor growth are
    core features of GALNT2-CDG and have no explanation in the lipid arm. A defect in
    insulin receptor glycosylation is a candidate explanation with a named substrate
    behind it, which is more than the neurological arm has.

    The caution is that the demonstration is murine. No study has shown altered insulin
    receptor glycosylation or insulin signalling in a GALNT2-CDG patient, so the human
    claim is an extrapolation and the entry marks it as such rather than curating a growth
    mechanism it cannot source in humans.
  evidence:
  - reference: PMID:35304331
    reference_title: "A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we identify the insulin receptor as a novel substrate of GalNAc-T2 and demonstrate
      that Galnt2-/- mice exhibit decreased adiposity, alterations in insulin signaling and
      a shift in energy substrate utilization in the inactive phase.
    explanation: >-
      Identifies the substrate and the metabolic consequence of losing its glycosylation.
      INDIRECT with respect to the human disease: the substrate identification and the
      signalling phenotype are both murine, so applying them to patients requires an
      inference step.
  - reference: PMID:35304331
    reference_title: "A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      It has recently become clear that loss of GALNT2 in rodents, cattle, nonhuman
      primates, and humans should be regarded as a novel congenital disorder of
      glycosylation that affects development and body weight.
    explanation: >-
      States that the growth/body-weight consequence of GALNT2 loss holds across four
      species including humans, which is what makes the murine insulin-receptor mechanism
      worth recording against the human growth phenotype rather than discarding.
  downstream:
  - target: Short Stature
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The edge this node's description already argues for in prose and did not draw. Typed
      with unknown intermediates rather than DIRECT for the reason stated above: the
      substrate identification and the growth phenotype are both murine, and no study has
      measured insulin receptor glycosylation or insulin signalling in a patient. It is the
      only candidate explanation for the growth phenotype with a named substrate behind it,
      which is why the edge is drawn at all rather than left out.

- name: Neurodevelopmental Dysfunction
  role: outcome
  biological_scale: ORGANISM
  description: >-
    The clinically dominant arm of the disease and the least mechanistically explained.
    What is established is that it is not secondary to the lipid phenotype and that it is
    reproduced in rodents, so it is a consequence of losing the enzyme rather than an
    ascertainment artefact of the human series.

    What is not established is the intermediate. No brain substrate of GalNAc-T2 has been
    linked to the phenotype, and the defining paper attributes it to multiple
    non-redundant substrates in various tissues without naming the relevant ones.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The multisystem nature of phenotypes in patients and rodent models of GALNT2-CDG
      suggest that there are multiple non-redundant protein substrates of GALNT2 in
      various tissues, including brain, which are critical to normal growth and
      development.
    explanation: >-
      The authors' own framing, and the reason this node's upstream edge is typed with
      unknown intermediates: the substrates are inferred to exist, not identified.
  downstream:
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The cardinal neurodevelopmental manifestation.
  - target: Intellectual Disability with Language Deficit
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The disproportionate language involvement is the feature that most distinguishes this
      disorder's cognitive profile.
  - target: Delayed Speech and Language Development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The developmental counterpart of the language deficit above.
  - target: Autistic Features
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reported across the cohort as part of the behavioural phenotype.
  - target: Epilepsy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Nothing connects the enzyme defect to seizure susceptibility mechanistically; the
      association is clinical.
  - target: Chronic Insomnia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Recorded as a distinct feature by the defining cohort rather than folded into the
      behavioural phenotype.
  - target: White Matter Changes on Brain MRI
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The one neurological finding with a structural correlate, and the reason
      oligodendrocytes are bound on this node alongside neurons. Whether the white matter
      change causes the clinical phenotype or accompanies it is not established, so this is
      drawn as a parallel consequence rather than as an intermediate.

- name: Decreased HDL Cholesterol
  role: outcome
  biological_scale: ORGANISM
  description: >-
    The biochemical endpoint of the lipid arm, and in practice the finding that flags the
    diagnosis in a child investigated for developmental delay.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dysmorphic features, decreased stature, and decreased high density lipoprotein
      cholesterol levels.
    explanation: >-
      States the HDL finding.

phenotypes:

- category: Neurologic
  name: Global Developmental Delay
  frequency: VERY_FREQUENT
  description: >-
    Present across the reported cohort, described as a general feature of the syndrome.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with GALNT2-CDG generally exhibit a syndrome characterized by global
      developmental delay, intellectual disability with language deficit, autistic
      features, behavioural abnormalities, epilepsy, chronic insomnia, white matter
      changes on brain MRI, dysmorphic features, decreased stature, and decreased high
      density lipoprotein cholesterol levels.
    explanation: >-
      Lists the feature. Graded VERY_FREQUENT rather than OBLIGATE because the source says
      "generally exhibit" rather than giving a per-patient count.

- category: Neurologic
  name: Intellectual Disability with Language Deficit
  frequency: VERY_FREQUENT
  description: >-
    Intellectual disability in which language is disproportionately affected. Recorded as
    two terms because the ontology has no single term for the combination, and the
    language component is the part clinicians describe as distinctive.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      global developmental delay, intellectual disability with language deficit, autistic
      features, behavioural abnormalities, epilepsy, chronic insomnia
    explanation: >-
      Names intellectual disability and its language component.

- category: Neurologic
  name: Delayed Speech and Language Development
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  description: >-
    The language component of the above, curated separately so it is queryable.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intellectual disability with language deficit
    explanation: >-
      The language deficit itself.

- category: Neurologic
  name: Autistic Features
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intellectual disability with language deficit, autistic features, behavioural
      abnormalities, epilepsy
    explanation: >-
      Names the autistic features.

- category: Neurologic
  name: Epilepsy
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white
      matter changes on brain MRI
    explanation: >-
      Names epilepsy as part of the syndrome.

- category: Neurologic
  name: Chronic Insomnia
  frequency: VERY_FREQUENT
  description: >-
    Chronic rather than intermittent, and prominent enough in the clinical description to
    be listed alongside the core neurological features rather than as a comorbidity.
  phenotype_term:
    preferred_term: Insomnia
    term:
      id: HP:0100785
      label: Insomnia
    temporality: CHRONIC
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain
      MRI
    explanation: >-
      Names the insomnia and its chronicity.

- category: Neurologic
  name: White Matter Changes on Brain MRI
  frequency: VERY_FREQUENT
  description: >-
    Reported as white matter change without a specified pattern, so the entry binds the
    general morphology term rather than a named leukodystrophy pattern it cannot support.
  phenotype_term:
    preferred_term: White matter changes on brain MRI
    term:
      id: HP:0002500
      label: Abnormal cerebral white matter morphology
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features
    explanation: >-
      Names the MRI finding, without a pattern, which is why the binding is the general
      term.

- category: Growth
  name: Short Stature
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      white matter changes on brain MRI, dysmorphic features, decreased stature, and
      decreased high density lipoprotein cholesterol levels.
    explanation: >-
      Names decreased stature. The mechanism is unexplained in humans; the insulin
      receptor node above records the murine candidate explanation and its limits.

- category: Craniofacial
  name: Dysmorphic Features
  frequency: VERY_FREQUENT
  description: >-
    Described as dysmorphic features without a specified gestalt in the abstract, so the
    binding is the general term.
  phenotype_term:
    preferred_term: Dysmorphic facial features
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      white matter changes on brain MRI, dysmorphic features, decreased stature
    explanation: >-
      Names the dysmorphism.

- category: Metabolic
  name: Decreased HDL Cholesterol
  frequency: VERY_FREQUENT
  description: >-
    The biochemical hallmark. In a child under investigation for developmental delay, a
    low HDL is the finding that should prompt apoC-III glycoform analysis.
  phenotype_term:
    preferred_term: Decreased HDL cholesterol concentration
    term:
      id: HP:0003233
      label: Decreased HDL cholesterol concentration
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dysmorphic features, decreased stature, and decreased high density lipoprotein
      cholesterol levels.
    explanation: >-
      States the HDL finding.

genetic:

- name: GALNT2
  gene_term:
    preferred_term: GALNT2
    term:
      id: hgnc:4124
      label: GALNT2
  relationship_type: CAUSATIVE
  notes: >-
    GALNT2 encodes GalNAc-T2, a Golgi-localized type II membrane glycosyltransferase and
    one of the twenty-isoenzyme GalNAc-T family. Expression is broad rather than
    tissue-restricted.

    The same gene has a second, entirely separate literature: the GALNT2 locus is a
    well-replicated common-variant association with HDL cholesterol and triglycerides in
    population cohorts. Those are regulatory variants of small effect and do not cause
    this disease. The overlap is mechanistically informative - both arms run through
    apoC-III O-glycosylation - but a reader should not take a GALNT2 lipid GWAS hit as
    evidence about GALNT2-CDG, and the evidence items here that draw on that literature
    are graded INDIRECT for exactly this reason.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GALNT2 encodes the Golgi-localized polypeptide N-acetyl-d-galactosamine-transferase
      2 isoenzyme.
    explanation: >-
      Establishes the gene product and its subcellular location.

inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Seven patients across four families with biallelic loss of function, which is the
    standard pattern for a congenital disorder of glycosylation.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report the clinical, biochemical, and molecular features of seven patients
      from four families with GALNT2-congenital disorder of glycosylation (GALNT2-CDG), an
      O-linked glycosylation disorder.
    explanation: >-
      The multiplex-family structure on which the recessive inference rests.

animal_models:

- name: Galnt2-null mouse
  species: Mouse
  genotype: Galnt2 knockout
  publication: PMID:32293671
  description: >-
    The principal model. It matters here for a specific reason: it establishes that the
    neurodevelopmental phenotype follows from loss of the enzyme rather than from
    ascertainment or from the consanguinity of the human families, which seven patients
    could not settle on their own.
  modeled_mechanisms:
  - target: Neurodevelopmental Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      Reproduces poor growth and neurodevelopmental abnormality, with cerebellar motor
      deficits, decreased sociability, and impaired sensory integration on behavioural
      testing.
    limitations: >-
      PARTIALLY rather than fully: the human phenotype's most prominent features are
      epilepsy, chronic insomnia and a disproportionate language deficit, and none of
      those has a behavioural counterpart reported in the mouse. Decreased sociability is
      an analogue of the autistic features at best.
    divergences:
    - divergence_type: SPECIES_MISMATCH
      materiality: QUALIFYING
      description: >-
        Language is the human phenotype's most distinctive feature and has no murine
        counterpart at all, so the model structurally cannot address the part of the
        disease that most affects patients. Epilepsy and chronic insomnia are likewise
        unreported in the model. SPECIES_MISMATCH is the closest available value;
        what is meant is an incomplete phenotype, for which ModelDivergenceTypeEnum
        currently has no term (see the discussion in CLAUDE.md, which anticipates
        INCOMPLETE_PHENOTYPE as a likely addition when the taxonomy is extended to
        animal models).
    readouts:
    - name: Behavioural testing for sociability, motor coordination and sensory processing
      target: Neurodevelopmental Dysfunction
      direction: ALTERED
      interpretation: >-
        Establishes a neurodevelopmental phenotype of enzyme loss in a second species.
      evidence:
      - reference: PMID:32293671
        reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          In behavioural studies, GALNT2-CDG mice demonstrated cerebellar motor deficits,
          decreased sociability, and impaired sensory integration and processing.
        explanation: >-
          The behavioural findings themselves.
  - target: Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
    relationship: MEASURES
    fidelity: HIGH
    model_scale: MOLECULAR
    description: >-
      Used as the system in which the GalNAc-T2-dependent O-glycosite network was mapped
      by quantitative glycoproteomics. Listed as MEASURES rather than RECAPITULATES
      because its role here is as an assay substrate: it is where the substrate set was
      determined, not a model of a lesion.
    limitations: >-
      The substrate network is murine. Conservation of individual O-glycosites between
      mouse and human is not established site by site, so the human substrate set is
      inferred from it rather than demonstrated.
    readouts:
    - name: Quantitative O-GalNAc glycoproteomics of Galnt2-null tissue
      target: Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
      direction: DECREASED
      interpretation: >-
        Identifies the glycoproteins that lose GalNAc-T2-specific glycans.
      evidence:
      - reference: PMID:37862385
        reference_title: "Quantitative mapping of the in vivo O-GalNAc glycoproteome in mouse tissues identifies GalNAc-T2 O-glycosites in metabolic disorder."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          We examined the Galnt2-null mouse model, which phenocopies congenital disorder
          of glycosylation involving GALNT2 and revealed a network of glycoproteins that
          lack GalNAc-T2-specific O-glycans.
        explanation: >-
          The mapping result.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human
      phenotype, including poor growth and neurodevelopmental abnormalities.
    explanation: >-
      Establishes the model as informative for the human disease, with the authors' own
      hedge ("much of") preserved.

- name: Galnt2-deficient rat
  species: Rat
  genotype: Galnt2 loss of function
  publication: PMID:32293671
  description: >-
    A second rodent species with the same result. Recorded because cross-species
    reproduction is what makes the growth and neurodevelopmental phenotype a robust
    consequence of enzyme loss rather than a strain artefact.
  modeled_mechanisms:
  - target: Neurodevelopmental Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      Reproduces poor growth and neurodevelopmental abnormalities.
    limitations: >-
      The abstract reports rat and mouse together without separating which findings come
      from which species, so nothing specific to the rat can be curated beyond the shared
      claim.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human
      phenotype, including poor growth and neurodevelopmental abnormalities.
    explanation: >-
      The only statement in which the rat appears; quoted rather than split, because
      splitting it would attribute to the rat a specificity the source does not give.

diagnosis:

- name: Apolipoprotein C-III Glycoform Analysis
  description: >-
    The disease-specific biochemical test. Because apoC-III is a non-redundant GalNAc-T2
    substrate, its complete loss of O-glycosylation is a direct readout of the enzyme
    defect - unlike transferrin isoform analysis, which is the standard CDG screen and
    interrogates N-glycosylation, a pathway this disease does not affect.

    That distinction is the practical point: a GALNT2-CDG patient can screen normal on the
    routine CDG test.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant
      substrate for GALNT2.
    explanation: >-
      Establishes the test's sensitivity in the reported cohort: all seven patients.
  - reference: PMID:34540767
    reference_title: "Congenital Disorders of Glycosylation: What Clinicians Need to Know?"
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: >-
      IEF of serum apolipoprotein C-III (apoC-III) is recommended to perform (Figure 1) to
      distinguish between an exclusive N-glycosylation defect and a combined disorder of N-
      and O-glycosylation
    explanation: >-
      Places the apoC-III test in the standard CDG diagnostic algorithm rather than treating
      it as a GALNT2-CDG-specific assay. INDIRECT: this is class-level guidance for the
      congenital disorders of glycosylation, not a statement about GALNT2-CDG.
  - reference: PMID:34540767
    reference_title: "Congenital Disorders of Glycosylation: What Clinicians Need to Know?"
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: >-
      However, some patients could also have an abnormal biosynthesis of core 1 O-glycans,
      including those with hemolytic uremic syndrome due to Streptococcus pneumoniae.
    explanation: >-
      The specificity caveat: an abnormal apoC-III profile is not on its own diagnostic of a
      GalNAc-T2 defect, which is the reason the molecular confirmation entry below exists
      rather than the glycoform test standing alone.
  notes: >-
    Specificity, not just sensitivity. The cohort finding above establishes that every
    reported patient had the abnormality; it does not establish that the abnormality is
    specific to this disease, and the cited review names at least one acquired cause of a
    core 1 O-glycan biosynthesis abnormality. Treat a positive glycoform result as an
    indication to sequence rather than as a diagnosis.

    The claim that transferrin analysis is normal in this disease is an inference from the
    fact that GALNT2 acts on O-glycosylation while transferrin screening interrogates
    N-glycosylation. No cited source states it for GALNT2-CDG patients, so it is recorded
    here in notes rather than as an evidenced diagnostic claim.

- name: Molecular Confirmation by Next-Generation Sequencing
  description: >-
    How the diagnosis is actually established. The apoC-III glycoform test above points at
    the enzyme, but every reported patient was confirmed by sequencing, and for a disorder
    this rare with a non-specific neurodevelopmental presentation the sequencing usually
    comes first: GALNT2-CDG is the kind of entity found by exome or genome sequencing in a
    child investigated for developmental delay, with the glycoform test used to confirm
    that the variants are doing what they appear to.
  evidence:
  - reference: PMID:34540767
    reference_title: "Congenital Disorders of Glycosylation: What Clinicians Need to Know?"
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: >-
      Since next-generation sequencing became more widely available, an improvement in
      diagnostics has been observed, with more patients and novel CDG subtypes being
      reported.
    explanation: >-
      Establishes sequencing as the route by which new CDG subtypes are identified and
      diagnosed. INDIRECT: this is a review of the congenital disorders of glycosylation as
      a class, not a statement about GALNT2-CDG, which it predates in wide recognition.

- name: Brain MRI
  description: >-
    Not diagnostic on its own, and included because the entry curates white matter changes
    as a phenotype: the finding has to be looked for to be recorded. In practice the MRI is
    performed as part of the workup for developmental delay rather than for suspected
    GALNT2-CDG.
  evidence:
  - reference: PMID:32293671
    reference_title: "Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      white matter changes on brain MRI
    explanation: >-
      Names the imaging finding in the defining cohort's phenotype description. INDIRECT
      because the source reports the finding rather than recommending the investigation.

treatments:

- name: Antiseizure Pharmacotherapy
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  description: >-
    Symptomatic management of the epilepsy. No GALNT2-CDG-specific antiseizure data exist
    and no agent is recommended here on disease-specific grounds; the entry records the
    treatment target without asserting a drug choice.
  target_mechanisms:
  - target: Epilepsy
    treatment_effect: MODULATES
    description: >-
      Suppresses the seizure phenotype without acting on the glycosylation defect that
      produces it.
  notes: >-
    No evidence item and no therapeutic_agent, deliberately. Naming an agent would imply
    a disease-specific recommendation the literature does not support.

- name: Developmental and Educational Support
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: developmental and educational intervention
    term:
      id: NCIT:C15315
      label: Rehabilitation
  description: >-
    Speech and language therapy has the clearest rationale given that language is
    disproportionately affected. As with the antiseizure entry, this is general practice
    for a neurodevelopmental disorder rather than a GALNT2-CDG finding.
  target_mechanisms:
  - target: Neurodevelopmental Dysfunction
    treatment_effect: MODULATES
    description: >-
      Addresses the functional consequences of the neurodevelopmental phenotype. It does
      not act on the mechanism, which is unidentified.
  notes: >-
    No evidence item; general practice, not disease-specific evidence.

- name: Genetic Counselling
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: >-
    Autosomal recessive, 25% recurrence risk per pregnancy for carrier couples.

differential_diagnoses:

- name: Other congenital disorders of glycosylation
  description: >-
    The clinical overlap is broad - developmental delay, epilepsy and dysmorphism are
    common to much of the CDG group - but the biochemical separation is clean. Most CDGs
    are N-glycosylation or combined disorders detectable by transferrin isoform analysis;
    this one is O-glycosylation only, so it separates on which assay is abnormal rather
    than on phenotype.

- name: Non-syndromic causes of low HDL cholesterol
  description: >-
    Relevant in the other direction. Low HDL is common and usually has nothing to do with
    glycosylation; it becomes a pointer to this disease only in the presence of the
    neurodevelopmental phenotype. Common GALNT2 regulatory variants also lower HDL in the
    general population without causing disease, which is the specific confusion to avoid.
  evidence:
  - reference: PMID:37834292
    reference_title: "Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Rs4846913-A, in the GALNT2-gene, was associated with decreased apo-CIII0a. This
      variant was associated with increased high-density lipoprotein cholesterol and
      decreased triglycerides
    explanation: >-
      Documents that common GALNT2 variation shifts HDL in the general population.
      INDIRECT because it supports the differential-diagnostic caution by analogy rather
      than reporting on GALNT2-CDG patients.

discussions:

- discussion_id: galnt2_brain_substrate_unknown
  kind: KNOWLEDGE_GAP
  prompt: >-
    Which GalNAc-T2 substrate or substrates mediate the neurodevelopmental phenotype of
    GALNT2-CDG?
  rationale: >-
    The lipid arm of this disease is mechanistically complete: a named substrate, a
    measured loss of its glycosylation, and a downstream clinical readout. The
    neurological arm, which is what actually disables patients, has none of that. The
    defining paper attributes it to non-redundant substrates in various tissues including
    brain, without identifying any of them, and the causal edge in this entry is typed
    INDIRECT_UNKNOWN_INTERMEDIATES to reflect that.

    The gap is tractable rather than merely acknowledged: the Galnt2-null glycoproteomic
    atlas already lists proteins that lose GalNAc-T2-specific glycans, so the candidates
    exist and the missing step is testing which of them matters in brain.

    It also has a practical consequence. Any therapeutic strategy aimed at the
    neurological phenotype needs a target, and there is currently no candidate to aim at.
  attaches_to:
  - pathophysiology#Neurodevelopmental Dysfunction
  - pathophysiology#Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
  proposed_experiments:
  - experiment_id: galnt2_brain_glycosite_mapping
    name: Brain-restricted O-glycosite mapping and functional follow-up in Galnt2-null rodents
    description: >-
      Apply the same quantitative O-GalNAc glycoproteomics to brain regions in Galnt2-null
      animals, restrict to sites lost in brain but retained elsewhere, and test the
      resulting candidates for a neurodevelopmental role.
    readouts:
    - name: Brain-specific GalNAc-T2-dependent O-glycosites
      target: pathophysiology#Loss of O-Glycosylation at Non-Redundant GalNAc-T2 Sites
      direction: DECREASED
      interpretation: >-
        A brain substrate lost only in the null identifies a candidate mediator.
    would_support:
    - pathophysiology#Neurodevelopmental Dysfunction
    supporting_outcome:
    - >-
      One or more neuronal or glial proteins with essential developmental functions lose
      O-glycosylation specifically in brain, and their independent disruption reproduces
      part of the behavioural phenotype.
    would_refute:
    - pathophysiology#Neurodevelopmental Dysfunction
    refuting_outcome:
    - >-
      No brain protein loses O-glycosylation beyond those already lost in other tissues,
      which would move the explanation away from a brain-specific substrate towards a
      systemic or developmental mechanism.

- discussion_id: galnt2_redundancy_paradox
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why does loss of one of twenty GalNAc-T isoenzymes produce a severe multisystem
    disease when the family is largely redundant?
  rationale: >-
    This is the question the disease poses to glycobiology rather than a gap in the
    clinical description. Redundancy is the family's defining property, and yet losing one
    member is not tolerated. The answer implied by the literature is that non-redundancy
    is site-specific rather than protein-specific - a given isoenzyme is the only one that
    will modify a particular residue in a particular sequence context - but which features
    of a site make it GalNAc-T2-exclusive is not established.

    Worth stating because it governs how much can be generalized from apoC-III. ApoC-III
    is the one non-redundant substrate that happens to be abundant, secreted and easy to
    assay, and there is no reason to think it is representative of the others.
  attaches_to:
  - pathophysiology#Loss of GalNAc-T2 Initiation of Mucin-Type O-Glycosylation

notes: >-
  Scope. This entry covers biallelic GALNT2 loss of function. Common regulatory variation
  at the GALNT2 locus that shifts HDL in the general population is a different phenomenon
  and is curated here only as differential-diagnostic context, with INDIRECT directness.

  Deep research. An OpenScientist deep-research report for this disease is committed
  alongside this entry. It was used as a lead-generator, not as a source: its
  reference-validation block records 13 of 13 references resolving with zero
  confabulation but only 3 of 13 judged on-topic, so most of what it cites is about
  GALNT2 the lipid-GWAS locus rather than about this disease. The one lead taken from it
  was the insulin receptor as a second non-redundant substrate, which was then verified
  against the primary paper and cited from there.

  Evidence base. Five references, after this review round added one. One - the 2020 Brain
  paper defining the disease - carries the clinical phenotype, the apoC-III finding and
  the rodent models; of the remaining four, two are mechanistic, one is
  population-genetic, and one is a class-level review of the congenital disorders of
  glycosylation cited only for the diagnostic route. An earlier version of this sentence
  said "five references ... the other three", which was both wrong and
  self-contradictory: there were four. The whole clinical phenotype
  therefore rests on a single cohort of seven patients, and every phenotype here is
  graded VERY_FREQUENT rather than OBLIGATE because that source describes the syndrome in
  aggregate ("generally exhibit") rather than giving per-patient counts.

  Identifiers. OMIM 618885 is the phenotype record for this disease. It is not recorded in
  a `mappings:` block because the schema has `icd10cm_mappings`, `icd11f_mappings`,
  `mondo_mappings` and `ncit_mappings` and no OMIM slot. The number here was read from
  MONDO's own `oio:hasDbXref` on MONDO:0030043 rather than taken from the deep-research
  report, which offers it alongside a gene OMIM number this entry does not record because
  it was not independently checked.

  What this entry does not assert. It does not name a mechanism linking the enzyme defect
  to the neurological phenotype; the relevant causal edge is typed
  INDIRECT_UNKNOWN_INTERMEDIATES and the gap is recorded as a discussion. It does not
  claim normal transferrin isoform analysis in patients, although that follows from the
  pathway involved, because no cited source reports it - that inference sits in the
  diagnosis notes instead. And it names no antiseizure agent, because no
  disease-specific data support one.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

Scope. This entry covers biallelic GALNT2 loss of function. Common regulatory variation at the GALNT2 locus that shifts HDL in the general population is a different phenomenon and is curated here only as differential-diagnostic context, with INDIRECT directness. Deep research. An OpenScientist deep-research report for this disease is committed alongside this entry. It was used as a lead-generator, not as a source: its reference-validation block records 13 of 13 references resolving with zero confabulation but only 3 of 13 judged on-topic, so most of what it cites is about GALNT2 the lipid-GWAS locus rather than about this disease. The one lead taken from it was the insulin receptor as a second non-redundant substrate, which was then verified against the primary paper and cited from there. Evidence base. Five references, after this review round added one. One - the 2020 Brain paper defining the disease - carries the clinical phenotype, the apoC-III finding and the rodent models; of the remaining four, two are mechanistic, one is population-genetic, and one is a class-level review of the congenital disorders of glycosylation cited only for the diagnostic route. An earlier version of this sentence said "five references ... the other three", which was both wrong and self-contradictory: there were four. The whole clinical phenotype therefore rests on a single cohort of seven patients, and every phenotype here is graded VERY_FREQUENT rather than OBLIGATE because that source describes the syndrome in aggregate ("generally exhibit") rather than giving per-patient counts. Identifiers. OMIM 618885 is the phenotype record for this disease. It is not recorded in a `mappings:` block because the schema has `icd10cm_mappings`, `icd11f_mappings`, `mondo_mappings` and `ncit_mappings` and no OMIM slot. The number here was read from MONDO's own `oio:hasDbXref` on MONDO:0030043 rather than taken from the deep-research report, which offers it alongside a gene OMIM number this entry does not record because it was not independently checked. What this entry does not assert. It does not name a mechanism linking the enzyme defect to the neurological phenotype; the relevant causal edge is typed INDIRECT_UNKNOWN_INTERMEDIATES and the gap is recorded as a discussion. It does not claim normal transferrin isoform analysis in patients, although that follows from the pathway involved, because no cited source reports it - that inference sits in the diagnosis notes instead. And it names no antiseizure agent, because no disease-specific data support one.

Review round 1: wire the phenotypes into the pathograph; add molecular diagnosis · 2026-09-12T12:59:13Z · View source

Addressed the three IMPORTANT findings in the CHANGES_REQUESTED review on PR #11718. Finding 1, pathograph disconnection. Nine of eleven phenotypes had no edges at all, so the rendered graph showed a lipid disease with an orphaned neurological phenotype list. Neurodevelopmental Dysfunction had no downstream edges despite the entry calling it the clinically dominant arm. Added bare-name downstream edges: Neurodevelopmental Dysfunction to its seven neurological phenotypes, the insulin-receptor node to Short Stature (the edge the node's own prose already argued for), and node 3 to Dysmorphic Features, which is morphogenetic rather than neurological so it is drawn from the substrate-loss node. All are typed INDIRECT_UNKNOWN_INTERMEDIATES, which is the honest typing: no substrate is identified for any of them. Added target_mechanisms to two of the three treatments (antiseizure to Epilepsy, developmental support to Neurodevelopmental Dysfunction); Genetic Counselling has no mechanism target and keeps none. Verified by rebuilding the graph rather than by reading the YAML: 20 edges, zero orphan targets, and isolated nodes down from 12 to 2. The two remaining are the GALNT2 gene node and Genetic Counselling, neither of which is a causal-graph participant. Finding 2, diagnosis. The section had only apoC-III glycoform analysis. Added molecular confirmation by next-generation sequencing, citing PMID:34540767, which was already cached in this PR but never cited, graded INDIRECT/OTHER because it is a class-level CDG review rather than a GALNT2-CDG source. Added brain MRI, since the entry curates white matter changes as a phenotype and the finding has to be looked for to be recorded. The transferrin IEF notes block was left unchanged, as the reviewer explicitly asked. Finding 3, notes miscount. The evidence-base sentence said five references and then said one plus the other three, which sums to four and there were four. Now five after this round's addition, itemised, with the earlier error stated rather than silently overwritten. Suggestions taken: oligodendrocyte (CL:0000128) added alongside neuron on the neurodevelopmental node, which also justifies the white-matter edge. OMIM 618885 recorded in notes rather than in mappings, because the schema has no OMIM mapping slot; the number was read from MONDO's own oio:hasDbXref rather than from the deep-research report. Suggestions declined with reasons given in the PR reply: HP:0000708 (is-a parent of an already-curated term, so it adds no queryable information), the gene OMIM number (not independently verified), and pruning the ten cached-but-uncited references. Validation: just validate passes, 32/32 snippets verified (was 30/30). check-duplicate-keys, check-entity-refs, check-causal-targets, check-qualifier-terms, check-enum-values all OK.

Create: GALNT2-CDG (MONDO:0030043) · 2026-09-11T21:59:26Z · View source

De-novo curation of GALNT2-CDG from claim issue #11713. Built the entry around the non-redundancy of GalNAc-T2 for a small substrate set rather than around a general loss of O-glycosylation, which does not occur. Kept the lipid arm (apoC-III -> low HDL, a named and measured substrate) separate from the neurological arm, whose causal edge is typed INDIRECT_UNKNOWN_INTERMEDIATES because no brain substrate has been identified. Added the insulin receptor as a second named substrate after an OpenScientist deep-research report surfaced it; the lead was verified against the primary paper and graded INDIRECT/MODEL_ORGANISM since the demonstration is murine. Population-genetic GALNT2 lipid-locus evidence is cited only as differential-diagnostic context and graded INDIRECT throughout, to keep common-variant HDL biology from reading as evidence about this Mendelian disease. Validated: linkml-validate, linkml-term-validator, 30/30 snippets verified against cached references, plus check-duplicate-keys, check-entity-refs, check-causal-targets and check-qualifier-terms. One reference_title was initially written from a reconstructed string and was corrected to the cached title after check-reference-titles flagged it.

OpenScientist ▸
GALNT2-Congenital Disorder of Glycosylation: A Comprehensive Disease Characterization
openscientist-autonomous 12 citations 2026-09-11T21:53:20.910315

GALNT2-Congenital Disorder of Glycosylation: A Comprehensive Disease Characterization

Disease: GALNT2-Congenital Disorder of Glycosylation (GALNT2-CDG) MONDO ID: MONDO:0030043 · OMIM (phenotype): #618885 · Gene: GALNT2 (OMIM 602274; HGNC:4124; locus 1q42.13) Category: Mendelian, autosomal recessive Report compiled from:* 14 confirmed findings, 21 reviewed papers, 5 investigation iterations

Summary

GALNT2-Congenital Disorder of Glycosylation (GALNT2-CDG) is an ultra-rare, autosomal-recessive inborn error of O-linked (mucin-type) protein glycosylation. It is caused by biallelic loss-of-function variants in GALNT2, the gene encoding polypeptide N-acetyl-galactosaminyltransferase 2 (GalNAc-T2), a Golgi-luminal enzyme that catalyzes the first committed step of mucin-type O-glycosylation—the transfer of N-acetylgalactosamine (GalNAc) onto serine and threonine residues of secreted and membrane proteins. Because GalNAc-T2 initiates glycosylation on a distinctive, largely non-redundant network of substrate proteins, its loss produces a characteristic, reproducible biochemical signature and a multisystem clinical syndrome. The disorder was defined in 2020 by Zilmer and colleagues in a cohort of seven patients from four families (PMID: 32293671).

Clinically, GALNT2-CDG presents from infancy as a neurodevelopmental syndrome: global developmental delay and intellectual disability with a prominent language deficit, autistic features and behavioural abnormalities, epilepsy, chronic insomnia, white-matter changes on brain MRI, dysmorphic features, decreased stature/poor growth, and decreased HDL cholesterol. The biochemical hallmark—present in every reported patient—is loss of O-glycosylation of apolipoprotein C-III (apoC-III), which serves as the diagnostic biomarker. A second, mechanistically important substrate is the insulin receptor, whose altered glycosylation links GalNAc-T2 to energy homeostasis, growth, and body weight. Diagnosis rests on apoC-III glycoform analysis (isoelectric focusing/mass spectrometry) combined with next-generation sequencing to confirm biallelic GALNT2 variants; standard transferrin isoelectric focusing (the classic screen for N-glycosylation CDGs) is not the primary test because GALNT2-CDG affects O-glycosylation.

There is no causative therapy; management is supportive and multidisciplinary (antiepileptic drugs, developmental/rehabilitation therapies, management of growth and dyslipidemia). The disorder is faithfully modeled in Galnt2-null rodents (mouse and rat), which recapitulate poor growth, neurodevelopmental abnormalities, cerebellar motor deficits, decreased sociability, and impaired sensory processing; a comparable loss-of-function state occurs naturally in cattle and nonhuman primates, underscoring cross-species conservation of the mechanism. Notably, GALNT2 has a "double life" in human genetics: rare biallelic loss-of-function causes the Mendelian CDG, while common regulatory variants at the 1q42 locus are among the best-established GWAS signals for HDL cholesterol and triglycerides, connecting this rare disease to population-scale lipid biology.

Section-by-Section Report

1. Disease Information

GALNT2-CDG is a congenital disorder of glycosylation affecting the initiation of mucin-type O-glycosylation. Zilmer et al. (2020) described it as a syndrome "characterized by global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels" (PMID: 32293671).

Key identifiers:

Resource Identifier
MONDO MONDO:0030043
OMIM (phenotype) #618885
OMIM (gene) 602274 (GALNT2*)
HGNC HGNC:4124
Locus 1q42.13
Disease class Congenital disorder of O-glycosylation (O-glycosylation subgroup)

Synonyms / alternative names: GALNT2-CDG; congenital disorder of glycosylation caused by GALNT2 deficiency; polypeptide N-acetylgalactosaminyltransferase 2 deficiency; GalNAc-T2 deficiency; O-linked glycosylation disorder due to GALNT2 loss of function.

Information source: The disease-level characterization is derived from aggregated case series and functional studies (a defining cohort of 7 patients from 4 families) supplemented by model-organism and human population-genetics data—not from large EHR datasets. Given the recency (2020) and rarity, disease-level resources rather than individual EHR mining underpin current knowledge.

2. Etiology

GALNT2-CDG is a purely monogenic disorder. It is caused solely by biallelic loss-of-function variants in GALNT2 (PMID: 32293671). No environmental, toxic, infectious, or lifestyle risk factors or protective factors have been described, and none are expected for a Mendelian glycosylation-initiation defect. Accordingly, gene–environment interactions are not applicable to disease causation.

  • Genetic risk factors: Biallelic (homozygous or compound-heterozygous) loss-of-function variants in GALNT2. Because all CDGs are autosomal recessive, consanguinity increases risk within affected families.
  • Environmental / lifestyle / infectious factors: Not applicable—no such contributors are reported.
  • Contrast with common-variant biology: Separately from the Mendelian disease, common regulatory variants at 1q42 (GALNT2) are established modifiers of plasma lipids in the general population (see Sections 4 and 9), but these do not "cause" the CDG.

3. Phenotypes

The phenotype spectrum derives from the defining cohort of 7 patients/4 families (PMID: 32293671), supplemented by rodent-model behavioural data. All features are congenital/early-onset, and the disorder is chronic.

Phenotype Type Suggested HPO term Onset Frequency (cohort)
Global developmental delay Clinical sign HP:0001263 Infancy Core / near-universal
Intellectual disability Clinical sign HP:0001249 Childhood Core
Language/speech deficit Clinical sign HP:0000750 Childhood Prominent
Autistic features Behavioural HP:0000729 Childhood Common
Behavioural abnormalities Behavioural HP:0000708 Childhood Common
Epilepsy / seizures Clinical sign HP:0001250 Infancy/childhood Common (core)
Chronic insomnia Behavioural/sleep HP:0100785 Childhood Common
Cerebral white-matter changes (MRI) Imaging/lab HP:0002500 Congenital/childhood Common
Dysmorphic features Physical HP:0001999 Congenital Common
Short stature / poor growth Physical HP:0004322 Congenital/infancy Common
Decreased HDL cholesterol Lab abnormality HP:0003233 (hypoalphalipoproteinemia) Congenital (biochemical) Characteristic
Loss of apoC-III O-glycosylation Lab abnormality (biomarker) — Congenital 100% (all patients)
  • Severity/progression: The neurodevelopmental disability is best characterized as static-to-slowly-evolving (chronic, lifelong). Epilepsy severity is variable. Growth impairment and dyslipidemia are persistent biochemical/physical features.
  • Quality-of-life impact: Intellectual disability, language deficit, autistic features, epilepsy, and chronic insomnia collectively impose substantial impact on daily functioning, communication, education, and family caregiving. No disease-specific QoL instrument (EQ-5D/SF-36/PROMIS) data have been published for GALNT2-CDG; QoL impact is inferred from the phenotype profile.
  • Motor involvement: Rodent models add cerebellar motor deficits and impaired sensory integration/processing, consistent with hypotonia/motor involvement in patients (PMID: 32293671).

4. Genetic / Molecular Information

  • Causal gene: GALNT2 (polypeptide N-acetylgalactosaminyltransferase 2), located at chromosome 1q42.13 (HGNC:4124; OMIM gene *602274). Zilmer et al. note "GALNT2 encodes the Golgi-localized polypeptide N-acetyl-d-galactosamine-transferase 2 isoenzyme" (PMID: 32293671).
  • Pathogenic variants: Biallelic loss-of-function variants, including missense variants abolishing enzyme activity and nonsense/frameshift (truncating) variants. All reported patients showed loss of apoC-III O-glycosylation, confirming functional loss of GalNAc-T2. Variant classification follows ACMG/AMP guidelines; truncating variants in this loss-of-function mechanism are typically pathogenic/likely pathogenic. (Variant-level ClinVar entries are limited by the disorder's rarity.)
  • Functional consequence: Loss of function (enzymatic loss of GalNAc-transferase activity). No gain-of-function or dominant-negative mechanism is described; heterozygous carriers are unaffected for the CDG.
  • Somatic vs germline: Germline, biallelic. (Somatic GALNT2 dysregulation is described in cancer biology—e.g., GALNT2 overexpression in lung adenocarcinoma, PMID: 33964375—but this is unrelated to the CDG.)
  • Allele frequency: Loss-of-function alleles are individually ultra-rare in gnomAD, consistent with an ultra-rare recessive disorder.
  • Modifier genes: None established. Given 20 GalNAc-T isoenzymes with overlapping specificities, partial functional redundancy for some substrates may modulate expressivity, but no specific modifiers are proven.
  • Epigenetic information: No disease-specific methylation/histone signature is established for GALNT2-CDG. (GALNT2 promoter methylation has been studied in cancer contexts—PMID: 33964375—not in the CDG.)
  • Chromosomal abnormalities: None; the disorder results from small-scale sequence variants, not large structural rearrangements.
  • Common-variant link: Kathiresan et al. (2008) identified 1q42 (GALNT2) as a genome-wide-significant HDL cholesterol locus in a GWAS of ~8,816 discovery and up to ~18,554 replication individuals: one new locus was found "with HDL cholesterol (1q42 in GALNT2)" (P<5×10⁻⁸) (PMID: 18193044). Vitali/Khetarpal/Rader (2017) list "novel loci implicated from GWAS including GALNT2, KLF14, and TTC39B" (PMID: 29103089).

5. Environmental Information

Not applicable. GALNT2-CDG is a monogenic recessive disorder with no reported environmental, occupational, toxic, lifestyle, or infectious contributors. No environmental modifiers of severity have been described.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. Biallelic loss-of-function variants in GALNT2 lead to absent/severely reduced GalNAc-T2 enzyme activity.
  2. Loss of GalNAc-T2 activity results in failure to transfer GalNAc to Ser/Thr residues on a non-redundant network of substrate glycoproteins in the Golgi apparatus (the first committed step of mucin-type O-glycosylation).
  3. Absent O-glycosylation of apolipoprotein C-III leads to altered lipoprotein metabolism and decreased HDL cholesterol (and serves as the diagnostic biomarker). (Demonstrated: apoC-III glycoform loss is universal in patients.)
  4. Branch — growth/metabolism: Loss of O-glycosylation of the insulin receptor leads to altered insulin-receptor post-translational modification and disturbed energy homeostasis, contributing to poor growth, short stature, and body-weight phenotypes. (Demonstrated in mice; inferred contributor in humans.)
  5. Branch — CNS: Loss of GalNAc-T2-specific O-glycans on neural/secreted substrates leads to impaired CNS development, manifesting as white-matter changes, developmental delay, intellectual disability with language deficit, autistic features, epilepsy, and chronic insomnia. (Association demonstrated; precise neural substrates partly inferred.)
  6. These converging effects result in the multisystem GALNT2-CDG phenotype present from birth and persisting as a chronic, lifelong disorder.

Supporting mechanistic detail:

  • Enzyme architecture / molecular pathway: GalNAc-Ts are "type II membrane proteins that consist of a Golgi luminal catalytic domain connected by a flexible linker to a ricin type lectin domain" and initiate mucin-type O-glycosylation by adding GalNAc to Ser/Thr (PMID: 30703750). The relevant pathway is mucin-type O-glycan biosynthesis (initiation); suggested GO term GO:0006493 (protein O-linked glycosylation).
  • Golgi localization: GalNAc-T2 requires its cytoplasmic tail plus transmembrane domain for correct Golgi targeting (PMID: 30084948), consistent with subcellular localization at GO:0005794 (Golgi apparatus).
  • Substrate network: The Galnt2-null mouse "phenocopies congenital disorder of glycosylation involving GALNT2 and revealed a network of glycoproteins that lack GalNAc-T2-specific O-glycans" (PMID: 37862385).
  • Energy homeostasis branch: "In mice, we identify the insulin receptor as a novel substrate of GalNAc-T2," and "the local effects of GalNAc-T2 are mediated through posttranslational modification of the insulin receptor" (PMID: 35304331).
  • Cellular processes / cell types: Broadly expressed secretory-pathway defect; GALNT2 "is widely expressed in most cell types and directs initiation of mucin-type protein O-glycosylation" (PMID: 32293671). CNS cell types implicated include neurons (CL:0000540) and oligodendrocytes/white-matter glia (CL:0000128) given white-matter involvement.
  • Metabolic changes: Dyslipidemia (decreased HDL-C) via apoC-III; systemic energy-homeostasis effects via insulin-receptor glycosylation. Suggested CHEBI entities: N-acetyl-D-galactosamine (CHEBI:28037), UDP-N-acetyl-α-D-galactosamine (donor substrate), cholesterol (CHEBI:16113).
  • Immune involvement / oxidative stress / fibrosis: No specific autoimmune, immunodeficiency, oxidative-stress, or fibrotic mechanism is established for this disorder.

7. Anatomical Structures Affected

  • Subcellular (site of the lesion): Golgi apparatus (GO:0005794)—the compartment where GalNAc-T2 acts. The secretory pathway broadly is affected.
  • Primary organ / system — central nervous system: White-matter changes on brain MRI (UBERON:0002316, white matter of the brain); brain (UBERON:0000955). Rodent data implicate the cerebellum (UBERON:0002037) via motor deficits.
  • Metabolic organs: Liver (UBERON:0002107) and systemic lipid/energy metabolism are implicated through apoC-III and insulin-receptor substrates.
  • Musculoskeletal / growth: Short stature and poor growth indicate skeletal/growth-axis involvement.
  • Craniofacial: Dysmorphic features indicate craniofacial (UBERON:0010313, head) involvement.
  • Body systems involved: Nervous system (primary), metabolic/endocrine (lipid and insulin signaling), musculoskeletal/growth.
  • Cell types: Neurons (CL:0000540), oligodendrocytes (CL:0000128); broadly, most secretory cell types given wide GALNT2 expression.
  • Lateralization: Bilateral/symmetric CNS involvement (no lateralization reported).

8. Temporal Development

  • Onset: Congenital / infantile. Developmental delay, poor growth, dysmorphism, and (in most) epilepsy present from infancy/early childhood (PMID: 32293671). Onset pattern is chronic/insidious rather than acute.
  • Progression: Chronic, lifelong. The neurodevelopmental disability is largely static-to-slowly-evolving. As a glycosylation-initiation defect present from development onward, the biochemical lesion is constant. Rodent models show growth failure and neurobehavioral deficits from early life (PMID: 32293671; PMID: 37862385).
  • Disease course pattern: Progressive-to-stable neurodevelopmental disability with episodic seizures.
  • Remission: No spontaneous remission; seizures may be treatment-responsive.
  • Critical periods: Early neurodevelopment (prenatal/infancy) is the key window of vulnerability; correspondingly, early developmental/rehabilitative intervention is the main opportunity to influence functional outcome.
  • Mortality/natural history: No natural-history mortality data are published, reflecting recency (2020) and rarity. The disorder is not reported as rapidly lethal; patients survive into childhood/adulthood with disability.

9. Inheritance and Population

  • Inheritance pattern: Autosomal recessive. "All CDGs are autosomal recessive disorders, with CDG type I being the most common" (PMID: 22469961). Defined by biallelic GALNT2 loss-of-function (PMID: 32293671).
  • Epidemiology: Ultra-rare. Defined in only 7 patients from 4 families; precise prevalence/incidence are unknown (no registry estimates published).
  • Penetrance / expressivity: Biallelic loss-of-function appears fully penetrant for the biochemical phenotype (100% loss of apoC-III O-glycosylation); clinical expressivity (e.g., seizure severity) is variable across the small cohort.
  • Genetic anticipation: Not applicable (not a repeat-expansion disorder).
  • Consanguinity / founder effects: Consanguinity contributes to recessive disease risk in affected families; no specific founder allele is established.
  • Carrier frequency: Not precisely established; heterozygous carriers are asymptomatic for the CDG. Common regulatory variants at 1q42 instead modulate HDL-C/triglycerides in the general population (PMID: 18193044).
  • Population demographics / geography / sex ratio: No ethnic predilection, geographic clustering, or sex bias is established; the cohort is too small to define these.

10. Diagnostics

  • Biochemical hallmark / biomarker: Loss of apoC-III sialylated O-glycoforms—"All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant substrate for GALNT2" (PMID: 32293671). ApoC-III isoform profiling (isoelectric focusing or mass spectrometry) is the relevant biochemical screen.
  • Why transferrin IEF is not primary: "Isoelectric focusing (IEF) of serum transferrin (Tf) is still the method of choice for diagnosing N-glycosylation disorders associated with sialic acid deficiency" (PMID: 34540767)—but GALNT2-CDG affects O-glycosylation, so transferrin IEF is not the primary test.
  • Genetic testing: Next-generation sequencing (WES/WGS) to confirm biallelic GALNT2 variants. "Since next-generation sequencing became more widely available, an improvement in diagnostics has been observed, with more patients and novel CDG subtypes being reported" (PMID: 34540767). Approach: apoC-III glycoform analysis + WES/WGS (or targeted CDG/O-glycosylation gene panel including GALNT2); single-gene testing where the phenotype is highly suggestive.
  • Imaging: Brain MRI to document white-matter changes (PMID: 32293671).
  • Laboratory: Lipid panel (decreased HDL cholesterol).
  • Clinical criteria / differential diagnosis: No formal diagnostic criteria exist. Differential diagnosis includes other O-glycosylation and multisystem CDGs, and other syndromic neurodevelopmental disorders with epilepsy and dysmorphism; the apoC-III O-glycoform abnormality plus biallelic GALNT2 variants distinguishes GALNT2-CDG.
  • Screening: Not currently part of newborn screening; cascade/carrier testing within affected families is appropriate.

11. Outcome / Prognosis

  • Survival/mortality: No published survival, life-expectancy, or mortality data. The disorder is not reported as rapidly lethal; patients survive into childhood/adulthood with disability.
  • Morbidity/function: Substantial lifelong morbidity from intellectual disability, language deficit, autistic features, epilepsy, chronic insomnia, and growth impairment. Long-term functional impairment is expected.
  • Quality of life: No disease-specific QoL metrics published; impact inferred as significant.
  • Complications: Seizure-related morbidity; developmental and behavioural sequelae; growth failure; dyslipidemia (decreased HDL-C, whose long-term cardiovascular implications in this recessive disorder are unstudied).
  • Recovery potential: No cure; supportive care can improve function but does not reverse the underlying defect.
  • Prognostic factors: Presumably seizure control and degree of developmental delay; not formally validated. ApoC-III glycoform status is a diagnostic rather than prognostic biomarker.

12. Treatment

No causative therapy exists. Management is supportive and multidisciplinary:

  • Antiepileptic drugs for seizures (NCIT: Anticonvulsant Agent).
  • Developmental and rehabilitative therapies (physical, occupational, speech/language therapy) for developmental delay and language deficit (NCIT: Rehabilitation Therapy).
  • Behavioural/sleep management for autistic features and chronic insomnia.
  • Growth and nutritional support; management of dyslipidemia as clinically indicated.

Reviews confirm the therapeutic gap: "causative treatment is available only for few CDG types" (PMID: 34540767), and "the lack of treatment for nearly all CDG types is striking" (PMID: 21970833). An emerging avenue is drug repositioning: "The (re)use of known drugs for novel medical purposes, known as drug repositioning, is growing for both common and rare disorders" (PMID: 35955863), though no repositioned agent is yet established for GALNT2-CDG.

  • Advanced therapeutics (gene/cell/RNA therapy): None approved or in trials specifically for GALNT2-CDG.
  • Pharmacogenomics / personalized medicine: No genotype-guided therapy established.

13. Prevention

  • Primary prevention: Not applicable in the population sense; disease occurrence is determined by inheritance of biallelic GALNT2 loss-of-function.
  • Genetic counseling and reproductive options: The principal preventive measures are genetic counseling, carrier testing, cascade screening within affected families, and—where desired—prenatal diagnosis or preimplantation genetic testing for at-risk couples.
  • Secondary/tertiary prevention: Early developmental intervention and seizure management to reduce complications and optimize function.
  • Immunization / public health / environmental interventions: Not applicable (no infectious or environmental etiology).

14. Other Species / Natural Disease

  • Cross-species conservation: "loss of GALNT2 in rodents, cattle, nonhuman primates, and humans should be regarded as a novel congenital disorder of glycosylation that affects development and body weight" (PMID: 35304331).
  • Naturally occurring disease: Reported in cattle (Bos taurus, NCBI Taxon 9913) and nonhuman primates, indicating veterinary/comparative relevance and evolutionary conservation of the phenotype (development and body-weight effects).
  • Orthologues: Galnt2 orthologues exist in mouse (Mus musculus, Taxon 10090), rat (Rattus norvegicus, Taxon 10116), cattle, and nonhuman primates.
  • Comparative pathology: Loss-of-function consistently affects growth/body weight and neurodevelopment across species, supporting a conserved mechanism.
  • Zoonotic potential: Not applicable (genetic, non-transmissible).

15. Model Organisms

  • Rodent models (mouse and rat): "Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human phenotype, including poor growth and neurodevelopmental abnormalities. In behavioural studies, GALNT2-CDG mice demonstrated cerebellar motor deficits, decreased sociability, and impaired sensory integration and processing" (PMID: 32293671).
  • Galnt2-null mouse: "phenocopies congenital disorder of glycosylation involving GALNT2 and revealed a network of glycoproteins that lack GalNAc-T2-specific O-glycans" (PMID: 37862385); used to map the in-vivo O-GalNAc glycoproteome and identify affected substrates.
  • Model types: Genetic knockout (mammalian). Model databases: MGI (mouse), RGD (rat).
  • Phenotype recapitulation: Strong—poor growth, neurodevelopmental and behavioural deficits, and the defining biochemical loss of GalNAc-T2-specific O-glycans are all reproduced.
  • Model limitations: Species differences in cognition/language limit modeling of the human intellectual-disability/language phenotype; the full human dysmorphic spectrum may not be captured.
  • Applications: Substrate-network discovery (glycoproteomics), energy-homeostasis and insulin-receptor mechanism studies, and a platform for testing candidate therapies.

Mechanistic Model / Interpretation

 Biallelic LoF in GALNT2 (1q42.13)
      │
      ▼
 Loss of GalNAc-T2 enzyme activity  ── Golgi-luminal, catalytic + ricin-type lectin domain
      │
      ▼
 Failure to initiate mucin-type O-glycosylation on a
 NON-REDUNDANT substrate network (Ser/Thr → GalNAc not added)
│                                   │
▼ (metabolic branch)                ▼ (CNS branch)
 apoC-III O-glycans lost ─► ↓ HDL-C   Neural/secreted substrates
 Insulin receptor O-glycans lost           lack O-glycans
│                                   │
▼                                   ▼
 Disturbed energy homeostasis,       White-matter changes, developmental
 poor growth, short stature          delay, ID + language deficit, autistic
                             features, epilepsy, chronic insomnia
└───────────────┬───────────────────┘
                ▼
     Multisystem, congenital, chronic GALNT2-CDG phenotype
   (apoC-III glycoform loss = diagnostic biomarker; NGS confirms)

Upstream vs downstream: The mutation and enzymatic loss are the upstream, non-redundant driver. The substrate-specific consequences (apoC-III → lipids; insulin receptor → growth/energy; neural substrates → CNS) are downstream and branch into the metabolic and neurodevelopmental arms of the phenotype. The universal loss of apoC-III O-glycosylation both proves the mechanism and provides the clinical biomarker.

Interpretation: GALNT2-CDG is a clean example of how loss of a single glycosylation-initiating enzyme, acting on a defined non-redundant substrate set, produces a coherent multisystem disorder. The same gene's common regulatory variation shapes population lipid traits—an unusually direct bridge between a Mendelian rare disease and quantitative human genetics.

Evidence Base

PMID Title (abbrev.) Evidence type Supports
32293671 Novel CDG caused by GALNT2 loss of function Human clinical + model Defining cohort; phenotype; apoC-III biomarker; MRI; rodent behaviour
35304331 GalNAc-T2 in energy homeostasis Human genetics + mouse Insulin receptor substrate; cross-species CDG; growth/body weight
37862385 O-GalNAc glycoproteome mapping Mouse / in vivo Galnt2-null phenocopy; affected O-glycoprotein network
30703750 GalNAc-Ts: redundancy to specificity Review / structural Enzyme architecture (catalytic + lectin); O-glycosylation initiation
30084948 GalNAc-T Golgi localization mechanisms In vitro GalNAc-T2 Golgi targeting requirements
18193044 Six new loci for lipids Human GWAS GALNT2 (1q42) as HDL-C locus
29103089 HDL metabolism & human genetics Review GALNT2 as GWAS-implicated HDL locus
34540767 CDG: what clinicians need to know Review Diagnostics (IEF, NGS); limited causative treatment
35955863 Drug repositioning for CDG Systematic review Emerging therapeutic strategy
21970833 CDG: sweet news Review Therapeutic gap across CDGs
35328062 Overview of metabolic epilepsies Review Epilepsy common in CDGs
22469961 Congenital disorders of glycosylation Review Autosomal recessive inheritance of CDGs

Key verbatim support: - Phenotype: "a syndrome characterized by global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels" (PMID: 32293671). - Biomarker: "All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant substrate for GALNT2" (PMID: 32293671). - Mechanism (energy): "In mice, we identify the insulin receptor as a novel substrate of GalNAc-T2" (PMID: 35304331). - Enzyme: "type II membrane proteins that consist of a Golgi luminal catalytic domain connected by a flexible linker to a ricin type lectin domain" (PMID: 30703750). - Inheritance: "All CDGs are autosomal recessive disorders, with CDG type I being the most common" (PMID: 22469961).

Limitations and Knowledge Gaps

  1. Very small human cohort. The disease is defined by 7 patients from 4 families (PMID: 32293671); prevalence, penetrance ranges, expressivity, natural history, survival, and QoL are not robustly quantified.
  2. No epidemiological estimates. Prevalence/incidence, carrier frequency, sex ratio, and geographic/ethnic distribution are undetermined.
  3. Incomplete CNS mechanism. The specific neural O-glycoprotein substrates that mediate white-matter changes, seizures, and language deficit are not fully identified; the CNS branch is partly inferred.
  4. No prognostic biomarkers or validated prognostic factors beyond the diagnostic apoC-III signature.
  5. No causative or disease-modifying therapy, and no clinical trials specific to GALNT2-CDG.
  6. Human vs model gaps. Rodent models capture growth and behaviour but not the human language/cognition and full dysmorphic spectrum.
  7. Long-term cardiovascular implications of the decreased-HDL phenotype in this recessive disorder are unstudied.

Proposed Follow-up Experiments / Actions

  1. Establish an international patient registry / natural-history study to define prevalence, phenotype frequencies, developmental trajectories, seizure outcomes, and survival.
  2. Comprehensive substrate-network glycoproteomics in human cells/tissues (extending the mouse O-GalNAc glycoproteome, PMID: 37862385) to identify the neural substrates driving CNS features.
  3. Standardize apoC-III O-glycoform diagnostics (IEF/MS protocols) and evaluate inclusion of GALNT2 in O-glycosylation/CDG gene panels and newborn/cascade screening frameworks.
  4. Mechanistic dissection of the insulin-receptor branch (PMID: 35304331) to test whether metabolic/growth phenotypes are tractable therapeutic targets.
  5. Therapeutic exploration via drug repositioning (PMID: 35955863) and preclinical gene-replacement/AAV or substrate-supplementation strategies in Galnt2-null rodents.
  6. Neurodevelopmental and QoL outcome measurement using standardized instruments to quantify disease burden and intervention benefit.
  7. Genotype–phenotype correlation analysis as new patients accrue, to assess expressivity and possible modifier effects among the 20-member GalNAc-T family.

Report compiled from 14 confirmed findings and 21 reviewed papers across 5 investigation iterations. Evidence types are labeled as human clinical, human genetics/GWAS, model organism, in vitro, review, or computational where relevant.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 21
Quoted claims found in source 21
Quoted claims not found in source 0
References weighed for topical relevance 13
On topic 3
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 24
Resolved 23
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 17
Terms named correctly 3
Terms named as a different term 9
Terms whose name is worth a second look 5

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0030043 (2 mentions) - the report calls it "MONDO"; MONDO calls it congenital disorder of glycosylation, type iit
  • HP:0001263 (1 mention) - the report calls it "Clinical sign"; HP calls it Global developmental delay
  • HP:0001249 (1 mention) - the report calls it "Clinical sign"; HP calls it Intellectual disability
  • HP:0000750 (1 mention) - the report calls it "Clinical sign"; HP calls it Delayed speech and language development
  • HP:0001250 (1 mention) - the report calls it "Clinical sign"; HP calls it Seizure
  • HP:0002500 (1 mention) - the report calls it "Imaging/lab"; HP calls it Abnormal cerebral white matter morphology
  • HP:0001999 (1 mention) - the report calls it "Physical"; HP calls it Abnormal facial shape
  • HP:0004322 (1 mention) - the report calls it "Physical"; HP calls it Short stature
  • UBERON:0002107 (1 mention) - the report calls it "Metabolic organs: Liver"; UBERON calls it liver**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0000729 (1 mention) - the report calls it "Behavioural"; HP calls it Autistic behavior, and lists "Autistic behaviour" among its other names
  • HP:0000708 (1 mention) - the report calls it "Behavioural"; HP calls it Atypical behavior, and lists "Behavioural changes" among its other names
  • HP:0100785 (1 mention) - the report calls it "Behavioural/sleep"; HP calls it Insomnia, and lists "Inability to sleep" among its other names
  • HP:0003233 (1 mention) - the report calls it "hypoalphalipoproteinemia"; HP calls it Decreased circulating HDL-C concentration, and lists "Hypoalphalipoproteinemia" among its other names
  • CL:0000540 (2 mentions) - the report calls it "Cell types: Neurons"; CL calls it neuron**